Intranasal Drug Delivery Devices Sales

Intranasal Drug Delivery Devices Market Outlook

The global intranasal drug delivery devices market is projected to reach approximately USD 5.96 billion by 2035, growing at a remarkable CAGR of around 12.5% during the forecast period from 2025 to 2035. This growth is fueled by the increasing prevalence of respiratory diseases such as allergic rhinitis and nasal congestion, which necessitate effective delivery methods for therapeutic agents. Furthermore, the growing preference for non-invasive drug administration methods is driving significant investments in research and development for innovative intranasal delivery technologies. The market is also benefitting from rising awareness regarding the advantages of intranasal drug delivery, including rapid absorption rates and enhanced bioavailability compared to traditional oral routes. As a result, this market is anticipated to witness substantial growth, propelled by technological advancements and an expanding range of applications in various therapeutic areas.

Growth Factor of the Market

The intranasal drug delivery devices market is experiencing robust growth due to a variety of factors that are enhancing their accessibility and effectiveness. The increasing incidence of chronic respiratory conditions, especially in urban areas, has necessitated the need for efficient and rapid delivery of medication, which intranasal devices can provide. Additionally, the rise in the elderly population who are more susceptible to respiratory ailments has further solidified the demand for such devices. Innovations in product design and technology, including the development of smart inhalers that provide real-time data to patients and healthcare providers, are also driving the market. Moreover, heightened awareness among patients and healthcare professionals about the benefits of intranasal delivery over traditional routes is contributing substantially to market growth. Finally, the shift towards home healthcare solutions, especially in the post-pandemic era, has increased the acceptance and adoption of intranasal devices.

Key Highlights of the Market

• The market is expected to grow at a CAGR of 12.5% from 2025 to 2035.
• Increasing prevalence of allergic rhinitis and nasal congestion is driving demand.
• Technological advancements in intranasal devices are enhancing delivery efficiency.
• Rising preference for non-invasive drug delivery methods among patients.
• Growth in home healthcare solutions is boosting the market for intranasal devices.

By Product Type

Nasal Sprays:

Nasal sprays are one of the most prevalent forms of intranasal drug delivery devices, primarily due to their ease of use and rapid onset of action. These devices allow for the efficient delivery of drugs directly into the nasal cavity, which facilitates quick absorption into the bloodstream. Nasal sprays are widely used for various applications, including the treatment of allergic rhinitis, migraines, and even certain vaccines. The market for nasal sprays is expanding significantly due to their convenience and the rising demand for self-administration options among patients. Furthermore, ongoing advancements in formulation technologies have led to the development of more sophisticated nasal sprays that enhance drug solubility and bioavailability, making them a preferred choice in the healthcare sector.

Nasal Drops:

Nasal drops represent another vital segment of the intranasal drug delivery devices market. They are typically utilized for the administration of liquid medications through the nasal cavity, making them suitable for a broad range of therapeutic applications, including decongestants and antihistamines. The simplicity of nasal drops combined with their effectiveness in delivering local or systemic effects contributes to their popularity. Additionally, the rising number of pediatric prescriptions for nasal drops due to their ease of administration is further driving this segment's growth. As healthcare providers increasingly recognize the value of nasal drops in treating various conditions, the demand for these devices is expected to continue to rise in the coming years.

Nasal Gels:

Nasal gels are gaining traction within the intranasal drug delivery market as they offer a unique formulation that can enhance drug residence time in the nasal cavity. This extended duration of action is particularly beneficial for drugs requiring sustained release. Nasal gels are being utilized for various therapeutic purposes, such as treating nasal congestion and delivering vaccines. The growing trend towards personalized medicine is also driving interest in nasal gels, as they can be tailored to meet specific patient needs and preferences. With the increasing focus on improving patient compliance and treatment outcomes, nasal gels are becoming an essential part of the intranasal drug delivery landscape.

Nasal Powders:

Nasal powders are an emerging segment within the intranasal drug delivery devices market, characterized by their unique ability to deliver dry formulations directly into the nasal cavity. This method of delivery allows for rapid absorption and can lead to improved therapeutic outcomes. Nasal powders are often employed in the administration of vaccines and other therapeutic agents, as they can enhance stability and shelf-life compared to liquid formulations. The market for nasal powders is expected to grow as more pharmaceutical companies invest in developing this delivery method, particularly for chronic conditions requiring long-term treatment, such as migraines and certain allergies.

Nasal Pumps:

Nasal pumps facilitate the administration of metered doses of medication, providing patients with a controlled and accurate delivery method. These devices are particularly useful for medications that require precise dosing, such as corticosteroids and other prescription drugs for respiratory conditions. The ability to deliver consistent doses enhances patient adherence to treatment regimens, which is crucial for managing chronic conditions. As the demand for reliable and efficient drug delivery systems continues to grow, nasal pumps are poised to capture a significant share of the intranasal drug delivery devices market. The integration of innovative technology into nasal pumps, including features like dose counters and patient feedback systems, further enhances their appeal in the healthcare landscape.

By Application

Allergic Rhinitis:

Allergic rhinitis represents a major application area for intranasal drug delivery devices, as millions of individuals worldwide suffer from this condition. The use of nasal sprays and drops for delivering antihistamines and corticosteroids has proven highly effective in alleviating symptoms such as nasal congestion, sneezing, and itchy eyes. The market for allergic rhinitis treatment is driven by factors such as increasing environmental allergens, changes in lifestyle, and greater awareness regarding allergy management. Innovative formulations and delivery devices are continuously emerging, enhancing the overall effectiveness of treatments available for allergic rhinitis, thus propelling this segment’s growth within the intranasal drug delivery market.

Nasal Congestion:

Nasal congestion is another prominent application driving the demand for intranasal drug delivery devices. This condition can result from colds, sinus infections, or allergies, and is often treated with decongestants delivered through nasal sprays and drops. The market for nasal congestion treatments is expanding, supported by an increasing prevalence of respiratory illnesses and a growing inclination towards self-medication. As patients seek fast-acting solutions for nasal congestion relief, the effectiveness of intranasal delivery systems in providing immediate relief is becoming increasingly recognized, thereby bolstering the growth prospects of this application segment.

Vaccination:

The application of intranasal drug delivery devices in vaccination is gaining traction, particularly in light of the increasing global focus on immunization against various infectious diseases. Intranasal vaccines offer several advantages, including non-invasiveness and the potential for needle-free administration, making them particularly appealing to patients who are apprehensive about needles. The COVID-19 pandemic has further accelerated research and development efforts aimed at creating effective intranasal vaccines. As healthcare providers and pharmaceutical companies explore new delivery methods to enhance vaccination rates, the market for intranasal devices for vaccination purposes is expected to experience substantial growth in the coming years.

Others:

The "Others" application segment encompasses a wide range of therapeutic areas where intranasal drug delivery devices can be utilized, including pain management and treatment of neurological conditions. The versatility of intranasal delivery systems allows for the administration of various drugs that can benefit from rapid absorption through the nasal mucosa, which can lead to expedited onset of action. The development of new formulations and ongoing clinical trials are expected to contribute to the expansion of this segment as healthcare providers and researchers continue to explore the vast potential of intranasal drug delivery across different medical interventions.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of intranasal drug delivery devices, particularly for patients requiring specialized treatments and medications. These pharmacies are equipped to provide a comprehensive range of products, including prescription nasal sprays and gels for hospital patients. The increasing complexity of patient care and the growing prevalence of respiratory illnesses are driving demand within hospital settings, where healthcare professionals rely on intranasal devices to effectively manage patient conditions. As hospital pharmacy services expand their capabilities and provide more tailored options for patients, the market for intranasal devices through this channel is expected to witness steady growth.

Retail Pharmacies:

Retail pharmacies serve as a primary distribution channel for over-the-counter intranasal drug delivery devices, making these products readily accessible to the general public. With a growing number of consumers seeking self-treatment options for conditions like allergic rhinitis and nasal congestion, retail pharmacies are adapting their inventory to include a wider range of nasal sprays, drops, and gels. The convenience of purchasing these products directly from local pharmacies fosters patient adherence to treatment, as it empowers individuals to manage their health conditions proactively. The competition among retail pharmacies also encourages pricing strategies that make intranasal devices more affordable, thus contributing to market growth.

Online Pharmacies:

Online pharmacies have become an increasingly popular distribution channel for intranasal drug delivery devices, with the convenience of online shopping catering to a tech-savvy population. The COVID-19 pandemic has significantly accelerated the adoption of e-commerce in the healthcare sector, as many patients sought to avoid crowded pharmacies while maintaining access to necessary medications. Online pharmacies offer a broad range of intranasal products, often at competitive prices, making them an attractive option for consumers. The ease of home delivery and discreet purchasing options enhance customer satisfaction, which is likely to continue driving growth in this segment as the trend of online shopping persists.

By Ingredient Type

Steroids:

Steroids are commonly used in intranasal drug delivery devices, particularly for managing inflammatory conditions such as allergic rhinitis and sinusitis. Intranasal corticosteroids offer targeted delivery to the nasal mucosa, which can significantly reduce systemic side effects while providing effective relief. The increasing prevalence of allergic conditions and the growing emphasis on minimizing medication side effects are driving the demand for steroid-based intranasal products. Ongoing research into new formulations and delivery methods is expected to enhance the efficacy of steroid-based treatments, further propelling this segment's growth in the market.

Antihistamines:

Antihistamines are another key ingredient type utilized in intranasal drug delivery devices, specifically designed to alleviate symptoms associated with allergic reactions. The rapid onset of action provided by nasal delivery systems makes antihistamines particularly effective for managing acute allergic responses, such as sneezing and nasal congestion. As the prevalence of allergies continues to rise, the demand for effective antihistamine formulations delivered via nasal sprays or drops is expected to increase. The ongoing development of new antihistamine options, combined with consumer preferences for rapid relief solutions, positions this segment for substantial growth in the intranasal drug delivery market.

Decongestants:

Decongestants are widely used in intranasal drug delivery devices to provide quick relief from nasal congestion caused by colds, allergies, or sinus infections. The effectiveness of decongestants delivered through nasal sprays is attributed to their ability to rapidly constrict blood vessels in the nasal passages, leading to decreased swelling and improved airflow. The rising incidence of respiratory infections and the quest for rapid treatment solutions are significant factors driving demand for decongestant-based intranasal products. As consumer preferences shift towards over-the-counter solutions for managing nasal congestion, the market for these devices is anticipated to grow significantly.

Vaccines:

Vaccines represent a vital ingredient type within the intranasal drug delivery market, especially as health authorities worldwide emphasize the importance of immunization against infectious diseases. The development of intranasal vaccines offers a non-invasive alternative to traditional injectable vaccines, which can improve patient compliance and acceptance, particularly in pediatric populations. Ongoing research aimed at enhancing the efficacy and stability of intranasal vaccines is expected to drive innovation in this segment. As vaccination campaigns expand globally, the demand for intranasal delivery systems for vaccines is predicted to increase significantly, supporting the growth of this ingredient type.

Others:

The "Others" category encompasses a variety of additional ingredient types that are utilized in intranasal drug delivery systems. This may include compounds aimed at treating conditions such as migraines, pain management, and neurological disorders. The versatility of intranasal drug delivery devices allows for the incorporation of a wide range of active ingredients, enhancing their appeal to both healthcare providers and patients. As ongoing research uncovers new therapeutic applications for intranasal delivery, this segment is expected to evolve and expand, contributing to the overall growth of the market.

By Region

The North American region leads the global intranasal drug delivery devices market, accounting for approximately 40% of the total market share. This dominance can be attributed to the high prevalence of allergic disorders and respiratory diseases in the region, as well as the presence of key pharmaceutical companies engaged in the development of innovative intranasal delivery systems. The market in North America is expected to grow at a CAGR of about 13% during the forecast period as advancements in technology and increasing healthcare expenditure continue to drive demand for effective treatment solutions. Furthermore, regulatory support for the approval of new intranasal products is expected to enhance market growth in this region.

Europe holds the second-largest share of the intranasal drug delivery devices market, representing approximately 30% of the total market value. The increasing awareness regarding the benefits of intranasal drug delivery, coupled with rising healthcare expenditures across European countries, is significantly contributing to market expansion. The region's strong focus on research and development, particularly in the arena of respiratory diseases and allergy treatments, is expected to foster growth in this segment. Asia Pacific is projected to experience the highest CAGR of around 15% during the forecast period, driven by the growing prevalence of chronic respiratory diseases, rising disposable income, and increasing access to healthcare services. The significant investments in healthcare infrastructure and ongoing initiatives to improve healthcare delivery systems in emerging economies like India and China are likely to enhance the market potential in this region.

Opportunities

The intranasal drug delivery devices market is poised to benefit from various opportunities stemming from advancements in technology and increased patient awareness. One significant opportunity lies in the development of smart nasal drug delivery systems capable of providing real-time feedback to patients and healthcare providers. These innovations could enhance patient adherence to treatment regimens, improve therapeutic outcomes, and streamline medication management. Furthermore, as healthcare professionals seek to provide more personalized treatment options, the trend toward tailored intranasal formulations is likely to gain momentum, thereby expanding market offerings and catering to diverse patient needs. The growing emphasis on preventive healthcare and vaccination campaigns provides additional avenues for market growth, particularly in the development of intranasal vaccines. As governments worldwide focus on immunization programs, the demand for effective intranasal delivery systems will continue to rise.

Moreover, the increasing shift toward home healthcare solutions presents a considerable opportunity for the intranasal drug delivery devices market. As more patients prefer to manage chronic conditions from the comfort of their homes, the convenience and ease of use associated with intranasal devices make them prime candidates for home healthcare applications. The development of user-friendly devices that facilitate self-administration without compromising efficacy will be critical in capturing this emerging market segment. Additionally, partnerships between pharmaceutical companies and technology firms can lead to the creation of innovative intranasal delivery solutions, driving further growth and enhancing the competitive landscape of the market.

Threats

Despite the promising growth trajectory of the intranasal drug delivery devices market, several threats could impede progress. One significant threat comes from regulatory challenges, which can lead to delays in product approvals and market entry for new intranasal devices. Regulatory bodies require extensive clinical data and safety assessments, which can prolong the development timeline and increase costs for manufacturers. Furthermore, stringent compliance requirements could deter smaller companies from entering the market, leading to reduced competition and innovation. Additionally, the market faces the threat of alternative drug delivery systems, such as oral and injectable methods, which may offer advantages in specific therapeutic areas. As healthcare providers become increasingly aware of the different options available, there is a risk that intranasal delivery may be overlooked for certain treatments, limiting market potential.

Another looming threat is the potential for adverse effects associated with the use of intranasal devices, which could lead to negative perceptions among patients. While intranasal drug delivery offers several advantages, any incidents of discomfort or complications could diminish patient trust in these products and hinder their adoption. Coupled with this, the rising awareness surrounding the potential misuse of intranasal drugs, particularly with substances that may have abuse potential, poses a challenge for companies operating in this space. To mitigate these threats, manufacturers must prioritize patient safety and invest in educational initiatives that promote responsible usage of intranasal drug delivery devices.

Competitor Outlook

• Johnson & Johnson
• GlaxoSmithKline
• Pfizer
• Boehringer Ingelheim
• AstraZeneca
• Novartis
• Sanofi
• Teva Pharmaceutical Industries
• Mylan N.V.
• Merck & Co.
• Hikma Pharmaceuticals
• Rovi Pharmaceuticals
• Endo International
• AptarGroup Inc.
• Impax Laboratories

The competitive landscape of the intranasal drug delivery devices market is characterized by the presence of major pharmaceutical companies and emerging players who are continuously striving to innovate and capture market share. The ongoing focus on research and development is leading to the introduction of novel products that enhance drug delivery efficiency and patient compliance. Companies are increasingly investing in partnerships and collaborations to leverage technological advancements and expand their product portfolios. This dynamic competition is fostering an environment where innovative intranasal devices are developed, catering to the growing needs of healthcare providers and patients alike.

Among the key players in the market, Johnson & Johnson stands out due to its extensive portfolio of intranasal products, particularly in the allergy and respiratory segments. The company's commitment to research and innovation has enabled it to maintain a competitive edge through the development of advanced formulations and delivery systems. GlaxoSmithKline, another prominent player, focuses on expanding its product offerings in the intranasal space, leveraging its expertise in developing effective medications for chronic respiratory conditions. Additionally, Pfizer is renowned for its strong presence in the market, particularly concerning intranasal vaccines, supporting its growth through ongoing research and development initiatives.

Furthermore, companies like Boehringer Ingelheim and AstraZeneca are actively participating in the market by introducing novel formulations and delivery methods to enhance patient outcomes. Boehringer Ingelheim, for example, is known for its focus on allergy treatments, while AstraZeneca is advancing its intranasal delivery systems for vaccines and therapeutic agents. The competitive landscape is marked by constant innovation, as companies strive to meet the evolving needs of patients and healthcare professionals while navigating regulatory challenges and market dynamics.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Pfizer
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Sanofi
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Mylan N.V.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 AstraZeneca
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Merck & Co.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AptarGroup Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 GlaxoSmithKline
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Johnson & Johnson
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Endo International
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Impax Laboratories
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Boehringer Ingelheim
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Rovi Pharmaceuticals
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Hikma Pharmaceuticals
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Intranasal Drug Delivery Devices Sales Market, By Application
    • 6.1.1 Allergic Rhinitis
    • 6.1.2 Nasal Congestion
    • 6.1.3 Vaccination
    • 6.1.4 Others
  • 6.2 Intranasal Drug Delivery Devices Sales Market, By Product Type
    • 6.2.1 Nasal Sprays
    • 6.2.2 Nasal Drops
    • 6.2.3 Nasal Gels
    • 6.2.4 Nasal Powders
    • 6.2.5 Nasal Pumps
  • 6.3 Intranasal Drug Delivery Devices Sales Market, By Ingredient Type
    • 6.3.1 Steroids
    • 6.3.2 Antihistamines
    • 6.3.3 Decongestants
    • 6.3.4 Vaccines
    • 6.3.5 Others
  • 6.4 Intranasal Drug Delivery Devices Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Intranasal Drug Delivery Devices Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Intranasal Drug Delivery Devices Sales market is categorized based on

By Product Type

• Nasal Sprays
• Nasal Drops
• Nasal Gels
• Nasal Powders
• Nasal Pumps

By Application

• Allergic Rhinitis
• Nasal Congestion
• Vaccination
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Steroids
• Antihistamines
• Decongestants
• Vaccines
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Johnson & Johnson
• GlaxoSmithKline
• Pfizer
• Boehringer Ingelheim
• AstraZeneca
• Novartis
• Sanofi
• Teva Pharmaceutical Industries
• Mylan N.V.
• Merck & Co.
• Hikma Pharmaceuticals
• Rovi Pharmaceuticals
• Endo International
• AptarGroup Inc.
• Impax Laboratories